JP2022550353A5 - - Google Patents

Info

Publication number
JP2022550353A5
JP2022550353A5 JP2022519331A JP2022519331A JP2022550353A5 JP 2022550353 A5 JP2022550353 A5 JP 2022550353A5 JP 2022519331 A JP2022519331 A JP 2022519331A JP 2022519331 A JP2022519331 A JP 2022519331A JP 2022550353 A5 JP2022550353 A5 JP 2022550353A5
Authority
JP
Japan
Prior art keywords
amino
methyl
naphthyridine
trans
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022519331A
Other languages
English (en)
Japanese (ja)
Other versions
JP7763753B2 (ja
JP2022550353A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/117487 external-priority patent/WO2021057853A1/en
Publication of JP2022550353A publication Critical patent/JP2022550353A/ja
Publication of JP2022550353A5 publication Critical patent/JP2022550353A5/ja
Application granted granted Critical
Publication of JP7763753B2 publication Critical patent/JP7763753B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022519331A 2019-09-26 2020-09-24 アザキノリン化合物およびその使用 Active JP7763753B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019108296 2019-09-26
CNPCT/CN2019/108296 2019-09-26
PCT/CN2020/117487 WO2021057853A1 (en) 2019-09-26 2020-09-24 Aza-quinoline compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2022550353A JP2022550353A (ja) 2022-12-01
JP2022550353A5 true JP2022550353A5 (cg-RX-API-DMAC7.html) 2023-08-22
JP7763753B2 JP7763753B2 (ja) 2025-11-04

Family

ID=75166744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519331A Active JP7763753B2 (ja) 2019-09-26 2020-09-24 アザキノリン化合物およびその使用

Country Status (11)

Country Link
US (2) US12544374B2 (cg-RX-API-DMAC7.html)
EP (1) EP4034535B1 (cg-RX-API-DMAC7.html)
JP (1) JP7763753B2 (cg-RX-API-DMAC7.html)
KR (1) KR102889562B1 (cg-RX-API-DMAC7.html)
CN (1) CN114746414B (cg-RX-API-DMAC7.html)
AU (1) AU2020355837B2 (cg-RX-API-DMAC7.html)
CA (1) CA3150284A1 (cg-RX-API-DMAC7.html)
DK (1) DK4034535T3 (cg-RX-API-DMAC7.html)
ES (1) ES3067468T3 (cg-RX-API-DMAC7.html)
IL (1) IL291499B2 (cg-RX-API-DMAC7.html)
WO (1) WO2021057853A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4034535T3 (da) 2019-09-26 2026-04-07 Novartis Ag Aza-quinolinforbindelser og anvendelser deraf
AR123185A1 (es) * 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
AR128015A1 (es) * 2021-12-16 2024-03-20 Transthera Sciences Nanjing Inc Inhibidor de cdk9 y uso del mismo
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
CN118515653B (zh) * 2024-07-23 2024-12-10 西湖制药(杭州)有限公司 一种ezh2特异性抑制剂及其制备方法和用途
CN118598873B (zh) * 2024-08-07 2024-11-19 艾斯拓康生物医药(天津)有限公司 一种手性的氮杂-喹啉类化合物的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Mek阻害剤による関節炎の治療
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
CA2478065C (en) 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
WO2014155301A1 (en) 2013-03-26 2014-10-02 Piramal Enterprises Limited Substituted bicyclic compounds as inhibitors of ezh2
MX375970B (es) 2014-12-23 2025-03-06 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos.
TW201708210A (zh) 2015-06-30 2017-03-01 葛蘭素史克智慧財產(第二)有限公司 Zeste同源物2增強子之抑制劑
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
MX2019004950A (es) 2016-10-28 2019-09-26 Icahn School Med Mount Sinai Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2.
DK4034535T3 (da) 2019-09-26 2026-04-07 Novartis Ag Aza-quinolinforbindelser og anvendelser deraf

Similar Documents

Publication Publication Date Title
RU2413727C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2023538159A5 (cg-RX-API-DMAC7.html)
AU2013300344B2 (en) N2,N4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer
JP2023123854A5 (cg-RX-API-DMAC7.html)
JP2010517946A5 (cg-RX-API-DMAC7.html)
RU2472797C2 (ru) ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА
JP2021529812A5 (cg-RX-API-DMAC7.html)
IL291499B2 (en) Aza-quinoline compounds and uses thereof
JP2021512059A5 (cg-RX-API-DMAC7.html)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
JP2013056930A5 (cg-RX-API-DMAC7.html)
IL291590B2 (en) Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
JP2020524719A5 (cg-RX-API-DMAC7.html)
RU2019136279A (ru) C5 -Анилинохиназолиновые соединения и их использование в лечении рака
RU2007134396A (ru) Химические соединения
JP2019535744A5 (cg-RX-API-DMAC7.html)
JPWO2020017587A5 (cg-RX-API-DMAC7.html)
JP2015531773A (ja) スルファモイル−アリールアミド及びb型肝炎の治療のための薬剤としてのその使用
JP2010530885A5 (cg-RX-API-DMAC7.html)
HRP20140975T1 (hr) Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
RU2013113733A (ru) Фармацевтически активные соединения в качестве ингибиторов axl
RU2017122062A (ru) Соединение 2-аминопиримидина и фармацевтическая композиция и применение данного соединения
RU2744168C1 (ru) Новое пиримидиновое производное, обладающее эффектом ингибирования роста раковых клеток, и содержащая его фармацевтическая композиция
RU2009125916A (ru) Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения